secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001193125-26-156127
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics appoints new CFO, additional execs to accelerate vopimetostat development
--------------------------------------------------------------------------------

- Daniella Beckman departs as CFO effective April 15; Matthew Gall named successor.
- Matthew Gall receives $540K base salary, 40% target bonus, 240K option shares, 40K RSUs.
- Jessica Newcomb appointed principal accounting officer; Yen-Ching Chua named Chief Development Operations Officer.
- Janice Kapty named SVP Corporate Strategy and Project Leadership; company focuses on vopimetostat for pancreatic cancer.
- Tango plans to present key clinical data in 2026, including combination trial with Revolution Medicines' RAS(ON) inhibitors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526156127/0001193125-26-156127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526156127/d144586d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-156127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer